Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C

Jonathan Stine, Javelle A. Wynter, Blake Niccum, Virginia Kelly, Stephen H. Caldwell, Neeral L. Shah

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalAnnals of Hepatology
Volume16
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Chronic Hepatitis C
Antiviral Agents
Diabetes Mellitus
Therapeutics
Fibrosis
Insulin
Insulin Resistance
Cohort Studies
Retrospective Studies
Genotype

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Stine, Jonathan ; Wynter, Javelle A. ; Niccum, Blake ; Kelly, Virginia ; Caldwell, Stephen H. ; Shah, Neeral L. / Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. In: Annals of Hepatology. 2017 ; Vol. 16, No. 2. pp. 215-220.
@article{e2d3532bd30d4644b918beb717a30233,
title = "Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C",
abstract = "Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8{\%}) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8{\%}. Thirty-one (18.5{\%}) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9{\%} were male and 61.5{\%} had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8{\%}) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95{\%} CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95{\%} CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.",
author = "Jonathan Stine and Wynter, {Javelle A.} and Blake Niccum and Virginia Kelly and Caldwell, {Stephen H.} and Shah, {Neeral L.}",
year = "2017",
month = "3",
day = "1",
doi = "10.5604/16652681.1231579",
language = "English (US)",
volume = "16",
pages = "215--220",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "2",

}

Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. / Stine, Jonathan; Wynter, Javelle A.; Niccum, Blake; Kelly, Virginia; Caldwell, Stephen H.; Shah, Neeral L.

In: Annals of Hepatology, Vol. 16, No. 2, 01.03.2017, p. 215-220.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C

AU - Stine, Jonathan

AU - Wynter, Javelle A.

AU - Niccum, Blake

AU - Kelly, Virginia

AU - Caldwell, Stephen H.

AU - Shah, Neeral L.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.

AB - Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.

UR - http://www.scopus.com/inward/record.url?scp=85013630322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013630322&partnerID=8YFLogxK

U2 - 10.5604/16652681.1231579

DO - 10.5604/16652681.1231579

M3 - Article

C2 - 28233744

AN - SCOPUS:85013630322

VL - 16

SP - 215

EP - 220

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 2

ER -